Marsh & McLennan Companies (MRSH) is back on investors’ radar after recent trading left the shares around $176.48, with one-day and past-week returns modestly positive while month and past 3 months performance remains negative.
See our latest analysis for Marsh & McLennan Companies.
That short-term rebound in the share price sits against a weaker backdrop, with a 1 year total shareholder return decline of 22.71% and a 5 year total shareholder return of 58.16%. As a result, recent momentum looks more muted than the longer term record.
If you are comparing Marsh & McLennan Companies with other financial names, it can be helpful to scan for resilience and growth drivers using a curated list of 20 top founder-led companies
With Marsh & McLennan Companies trading at $176.48 and sitting at a 38.05% modelled intrinsic discount, the key question for you is whether this reflects an undervalued insurer or whether the market is already pricing in future growth.
Most Popular Narrative: 14.8% Undervalued
On the most followed view, Marsh & McLennan Companies' fair value of $207.20 sits ahead of the last close at $176.48, putting the current discount under the spotlight.
Strategic investments in digital transformation, advanced analytics, and AI (for example, proprietary data tools for risk modeling and agentic interfaces) are expected to improve operational efficiency and product and service offerings, enabling margin expansion and net earnings growth through improved client retention and lower cost to serve.
Curious what kind of revenue pace, margin profile, and future earnings multiple are built into that $207.20 figure? The narrative combines steady top line assumptions with firmer profitability and a premium valuation hurdle that some investors may find ambitious. The full breakdown shows exactly how those moving parts add up and how sensitive the fair value is to even small changes.
Result: Fair Value of $207.20 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this depends on property and reinsurance pricing not weakening further and on acquisitions like McGriff performing well, because missteps in these areas could pressure margins and growth.
Find out about the key risks to this Marsh & McLennan Companies narrative.
Next Steps
With mixed signals across price performance and valuation, the real question is what you take away from the full picture of risks and rewards, so it is worth moving quickly from headlines to hard numbers and weighing the 4 key rewards and 2 important warning signs
Looking for more investment ideas?
If you stop at just one company, you could miss opportunities that fit your goals better, so take a few minutes to scan these curated ideas before you move on.
- Target reliable compounding potential with companies that pair quality with attractive pricing by reviewing the 53 high quality undervalued stocks.
- Prioritize income by checking out the 13 dividend fortresses for companies offering higher yields that might suit a cash flow focused portfolio.
- Seek staying power in tougher markets by scanning the 68 resilient stocks with low risk scores for businesses with more resilient risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com